Literature DB >> 10071185

Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency.

A B Van Kuilenburg1, P Vreken, N G Abeling, H D Bakker, R Meinsma, H Van Lenthe, R A De Abreu, J A Smeitink, H Kayserili, M Y Apak, E Christensen, I Holopainen, K Pulkki, D Riva, G Botteon, E Holme, M Tulinius, W J Kleijer, F A Beemer, M Duran, K E Niezen-Koning, G P Smit, C Jakobs, L M Smit, A H Van Gennip.   

Abstract

Dihydropyrimidine dehydrogenase (DPD) deficiency is an autosomal recessive disease characterised by thymine-uraciluria in homozygous deficient patients and has been associated with a variable clinical phenotype. In order to understand the genetic and phenotypic basis for DPD deficiency, we have reviewed 17 families presenting 22 patients with complete deficiency of DPD. In this group of patients, 7 different mutations have been identified, including 2 deletions [295-298delTCAT, 1897delC], 1 splice-site mutation [IVS14+1G>A)] and 4 missense mutations (85T>C, 703C>T, 2658G>A, 2983G>T). Analysis of the prevalence of the various mutations among DPD patients has shown that the G-->A point mutation in the invariant splice donor site is by far the most common (52%), whereas the other six mutations are less frequently observed. A large phenotypic variability has been observed, with convulsive disorders, motor retardation and mental retardation being the most abundant manifestations. A clear correlation between the genotype and phenotype has not been established. An altered beta-alanine, uracil and thymine homeostasis might underlie the various clinical abnormalities encountered in patients with DPD deficiency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071185     DOI: 10.1007/pl00008711

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  61 in total

1.  Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.

Authors:  Hélène Mounier-Boutoille; Michèle Boisdron-Celle; Estelle Cauchin; Jean-Paul Galmiche; Alain Morel; Erick Gamelin; Tamara Matysiak-Budnik
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

2.  Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine.

Authors:  Timur Cerić; Nermina Obralić; Lejla Kapur-Pojskić; Drazenka Macić; Semir Beslija; Anes Pasić; Sejla Cerić
Journal:  Bosn J Basic Med Sci       Date:  2010-05       Impact factor: 3.363

3.  Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.

Authors:  Saranya Kodali; Venu Bathini; Paul Rava; Eswar Tipirneni
Journal:  J Gastrointest Cancer       Date:  2017-03

4.  Dihydropyrimidine dehydrogenase deficiency presenting at birth.

Authors:  N A Al-Sanna'a; A B P Van Kuilenburg; T M Atrak; M A Abdul-Jabbar; A H Van Gennip
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

5.  Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.

Authors:  Hea-Kyoung Cho; Eun-Sook Lee; Jung-Won Lee; Jong-Kook Park; Jin-Hyoung Kang; Kyung-Shik Lee; Chang-Koo Shim; Suk-Jae Chung; Dae-Duk Kim; Hyo-Jeong Kuh
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-04       Impact factor: 4.553

6.  Dihydropyrimidine dehydrogenase deficiency and acute neurological presentation.

Authors:  A Fiumara; A B P van Kuilenburg; U Caruso; C Nucifora; E Marzullo; R Barone; C Meli; A H van Gennip
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 7.  Inborn errors of purine and pyrimidine metabolism.

Authors:  A Jurecka
Journal:  J Inherit Metab Dis       Date:  2009-03-15       Impact factor: 4.982

8.  Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3).

Authors:  André B P van Kuilenburg; Judith Meijer; Adri N P M Mul; Raoul C M Hennekam; Jan M N Hoovers; Christine E M de Die-Smulders; Peter Weber; Andrea Capone Mori; Jörgen Bierau; Brian Fowler; Klaus Macke; Jörn Oliver Sass; Rutger Meinsma; Julia B Hennermann; Peter Miny; Lida Zoetekouw; Raymon Vijzelaar; Joost Nicolai; Bauke Ylstra; M Estela Rubio-Gozalbo
Journal:  Hum Genet       Date:  2009-03-19       Impact factor: 4.132

9.  Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.

Authors:  F Aminkeng; C J D Ross; S R Rassekh; L R Brunham; J Sistonen; M-P Dube; M Ibrahim; T B Nyambo; S A Omar; A Froment; J-M Bodo; S Tishkoff; B C Carleton; M R Hayden
Journal:  Pharmacogenomics J       Date:  2013-04-16       Impact factor: 3.550

10.  Genetic variation in the one-carbon transfer pathway and ovarian cancer risk.

Authors:  Linda E Kelemen; Thomas A Sellers; Joellen M Schildkraut; Julie M Cunningham; Robert A Vierkant; V Shane Pankratz; Zachary S Fredericksen; Madhura K Gadre; David N Rider; Mark Liebow; Ellen L Goode
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.